News coverage about Regenxbio (NASDAQ:RGNX) has been trending somewhat positive this week, AlphaOne Sentiment reports. The research group, a subsidiary of Accern, scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Regenxbio earned a daily sentiment score of 0.25 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Alpha One’s rankings:
- Regenxbio (RGNX) Receiving Very Positive Media Coverage, Report Finds (americanbankingnews.com)
- Chardan Capital Increases Regenxbio Inc (RGNX) Price Target to $50.00 (americanbankingnews.com)
- Regenxbio (RGNX) Given Daily News Impact Score of -0.04 (americanbankingnews.com)
- Regenxbio Inc (RGNX) Upgraded to Hold at Zacks Investment Research (americanbankingnews.com)
Several equities analysts have issued reports on the stock. Chardan Capital lifted their price target on shares of Regenxbio from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, April 11th. TheStreet lowered shares of Regenxbio from a “c-” rating to a “d+” rating in a report on Friday, April 7th. Finally, Zacks Investment Research raised shares of Regenxbio from a “sell” rating to a “hold” rating in a report on Thursday, January 12th.
Regenxbio (NASDAQ:RGNX) remained flat at $20.60 during midday trading on Friday. The company’s stock had a trading volume of 111,155 shares. Regenxbio has a 52 week low of $7.07 and a 52 week high of $24.55. The stock’s market cap is $546.17 million. The company has a 50 day moving average price of $20.00 and a 200-day moving average price of $19.19.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, March 7th. The biotechnology company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.01. The business earned $1.70 million during the quarter. Regenxbio had a negative net margin of 661.81% and a negative return on equity of 24.21%. Analysts forecast that Regenxbio will post ($3.07) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/04/21/regenxbio-rgnx-receives-media-sentiment-score-of-0-25-updated.html.
Regenxbio Company Profile
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related companies with MarketBeat.com's FREE daily email newsletter.